home · filing · 0001104659-22-033991
8-K filed March 15, 2022, 7:59 PM ET
ticker VYNE
CIK 0001566044
other material
confidence high
sentiment neutral
materiality 0.70
VYNE Therapeutics enters $30M equity line with Lincoln Park Capital; names Tyler Zeronda CFO
VYNE Therapeutics Inc.
Up to $30M of common stock can be sold to Lincoln Park over 36 months; 1,667,593 commitment shares issued.
Regular purchases up to 200,000 shares/day (increased to 400,000 if closing price >= $1.00); pricing at discount to market.
Exchange cap of 11,227,637 shares (19.99% of outstanding) unless stockholder approval or avg price >= $0.545.
Tyler Zeronda appointed CFO and Treasurer effective March 14, 2022; annual base salary $340,000 with 40% target bonus.
Proceeds from equity line expected to be used for working capital and general corporate purposes.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-03-14
Filed March 15, 2022, 7:59 PM ET
On March 14, 2022, the Company named Tyler Zeronda as the Chief Financial Officer and Treasurer of the Company effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tyler Zeronda was named as Chief Financial Officer and Treasurer at VYNE Therapeutics Inc..
Action named
Role Chief Financial Officer and Treasurer
Exact text from the filing
On March 14, 2022, the Company named Tyler Zeronda as the Chief Financial Officer and Treasurer of the Company effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-22-033991
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.